ArticleFrontiers in genetics2026
Integrated hearing and genetic screening for neonatal deafness in a resource-limited region: insights from Qingyuan, China.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to delineate the prevalence and mutation spectrum of deafness-associated genes among newborns in a resource-limited region of China, and to assess the diagnostic yield of combined hearing and genetic screening. Methods: From May 2017 to May 2023, 22,819 newborns underwent concurrent hearing screening and genetic screening for deafness-associated mutations using 9-variant or 23-variant microarrays targeting GJB2, SLC26A4, GJB3, and mitochondrial 12SrRNA. Whole-exome sequencing was performed in selected cases with inconclusive results. All infants were followed until 2.5 years of age. Results: Hearing screening confirmed hearing loss in 25 infants (0.11%). Genetic screening identified 994 (4.36%) mutation carriers, predominantly GJB2 (3.31%) and SLC26A4 (0.78%). Among 351 GJB2 109G>A heterozygotes, all had normal hearing at 2.5 years. Among 43 homozygotes, 7 (16.28%) had congenital deafness; the rest remained normal. All 42 mitochondrial mutation carriers remained deafness-free after preventive education. The 23-variant panel detected 24.73% positive cases (225-fold vs. hearing alone). WES resolved 80% of ambiguous cases. Conclusion: GJB2 and SLC26A4 are the predominant deafness genes in this region. Combined screening identifies distinct risk groups, heterozygotes for reproductive counselling, mitochondrial carriers for prevention, and homozygotes for early intervention. Long-term follow-up of normal-hearing homozygotes showed low short-term delayed-onset risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.